SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q1 Net Income USD -8.407 Million
SELLAS Life Sciences 2025 net loss narrows, cash position strengthens
Brief: SELLAS Life Sciences FY Net Income USD -26.863 Million
Brief: Sellas Life Sciences Enters Agreement With Impact-Aml To Expand SLS009 Clinical Program Into Europe
SELLAS Life Sciences Q3 net loss narrows to $6.8 mln
Brief: SELLAS Life Sciences Q3 Net Income USD -6.791 Million
Brief: SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
Brief: Sellas Life Sciences Secures $23.6 Million in Gross Proceeds Through Institutional Warrant Exercise
Sellas Life Sciences Group Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: SELLAS Life Sciences Q2 Net Income USD -6.601 Million
Sellas Life Sciences Group Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Sellas Gets Green Light to Continue Phase 3 REGAL Trial of GPS in AML After Positive Data Review
Sellas Life Sciences Group Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: SELLAS Life Sciences Q1 Net Income USD -5.813 Million
Sellas Life Sciences Group Inc expected to post a loss of 10 cents a share - Earnings Preview